153 related articles for article (PubMed ID: 22898148)
1. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children.
Punpanich W; Nithitamsakun N; Treeratweeraphong V; Suntarattiwong P
Int J Infect Dis; 2012 Nov; 16(11):e811-5. PubMed ID: 22898148
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Mortality in Children with
Choe YJ; Lee HJ; Choi EH
Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349
[No Abstract] [Full Text] [Related]
3. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
Vandepitte WP; Berge J; Andersson R
J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study.
Thatrimontrichai A; Apisarnthanarak A; Chanvitan P; Janjindamai W; Dissaneevate S; Maneenil G
Pediatr Infect Dis J; 2013 Feb; 32(2):140-5. PubMed ID: 22935872
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
Munoz-Price LS; Zembower T; Penugonda S; Schreckenberger P; Lavin MA; Welbel S; Vais D; Baig M; Mohapatra S; Quinn JP; Weinstein RA
Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1057-62. PubMed ID: 20715975
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
10. Research and analysis of 74 bloodstream infection cases of Acinetobacter baumannii and drug resistance.
Wu HG; Liu WS; Zhu M; Li XX
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1782-1786. PubMed ID: 29630127
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.
Lee YT; Chiang MC; Kuo SC; Wang YC; Lee IH; Chen TL; Yang YS
PLoS One; 2016; 11(9):e0163271. PubMed ID: 27644087
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
14. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit.
Kim SY; Jung JY; Kang YA; Lim JE; Kim EY; Lee SK; Park SC; Chung KS; Park BH; Kim YS; Kim SK; Chang J; Park MS
J Korean Med Sci; 2012 Aug; 27(8):939-47. PubMed ID: 22876063
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors, Clinical Presentation, and Outcome of
Ballouz T; Aridi J; Afif C; Irani J; Lakis C; Nasreddine R; Azar E
Front Cell Infect Microbiol; 2017; 7():156. PubMed ID: 28523249
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
19. The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.
Park KH; Shin JH; Lee SY; Kim SH; Jang MO; Kang SJ; Jung SI; Chung EK; Ko KS; Jang HC
PLoS One; 2014; 8(6):e65026. PubMed ID: 23755171
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y
J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
